SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.1600.0%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Craig Slotoroff who started this subject7/30/2001 1:11:52 PM
From: 613   of 1605
 
Vasomedical In Agreement With FDA On Investigation Plan
July 30, 2001
WESTBURY, N.Y. -(Dow Jones)- The Food and Drug Administration approved Vasomedical Inc.'s (VASO) study on the effectiveness of enhanced external
counterpulsation (EECP) in patients with congestive heart failure.
In a press release Monday, the company said it expects that the full submission of data in the agreed-upon protocol will reduce the chance of an FDA request
for additional information.
EECP is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system. The therapy is designed to increase circulation in areas of
the heart with less-than-adequate blood supply, and Vasomedical believes that it may restore systemic vascular function.
The company began enrolling patients in March for an EECP trial and expects the trial to take up to two years to complete.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News